Abaxis, Inc., a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, and privately-held LamdaGen Corporation, an optical biosensor company, announced today an R&D agreement to integrate LamdaGen's high-sensitivity Plasmonic ELISA technology on the Abaxis Piccolo and VetScan rotors. System feasibility testing is currently underway.
LamdaGen's patented biosensor platform is based upon LSPR (Localized Surface Plasmon Resonance) and provides rapid, quantitative diagnostic results with broad dynamic range and detection levels in the femtomolar range.
"We believe that LamdaGen's technology will provide a unique opportunity for Abaxis to integrate a high sensitivity immuno-based system onto our existing rotor-based platforms. This would allow us to provide both our existing clinical chemistry menu together with a wide range of high-sensitivity immunoassays, all within the scope of our present designs. If proven viable, both medical and veterinary customers will be able to simultaneously analyze for chemistry parameters as well as for infectious disease, hormones and a wide range of other markers on the same rotor," commented Clint Severson, Chief Executive Officer of Abaxis. "The ability to unify both diagnostic systems onto our existing rotor will greatly expand Abaxis' global diagnostic offerings."
"Abaxis is a leader in the POC industry, and we are very excited to collaborate with them in shaping the future of diagnostic testing," added Randy Storer, Chief Executive Officer of LamdaGen.